Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force

Averna M., Banach M., Bruckert E., Drexel H., Farnier M., Gaita D., ...More

ATHEROSCLEROSIS, vol.325, pp.99-109, 2021 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 325
  • Publication Date: 2021
  • Doi Number: 10.1016/j.atherosclerosis.2021.03.039
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE, Food Science & Technology Abstracts, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.99-109
  • Hacettepe University Affiliated: Yes


Background and aims: This European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in highrisk and very-high-risk patients.